Orthofix Medical (OFIX) concentration risks

Orthofix Medical's revenue is heavily weighted toward a single product segment: Global Spine accounted for 84% of total net sales in 2025, with Global Limb Reconstruction contributing the remaining 16%. This is a structural concentration in the business's product mix rather than a dependency on any single customer or counterparty, but it means Global Spine's performance is by far the dominant driver of consolidated results, leaving Global Limb Reconstruction a comparatively small offsetting contributor. Separately, the company's ability to market certain tissue products depends on its supplier continuing to have access to donated human cadaveric tissue — a dependency-type exposure tied to a specific supplier relationship and, ultimately, to donor tissue availability, which is a different kind of risk entirely from the segment mix. Netting these out, the Global Spine concentration is the more structurally significant exposure since it defines the great majority of the revenue base, while the cadaveric tissue supplier dependency is narrower in scope but idiosyncratic — a disruption there would affect a specific tissue product line rather than the broader Global Spine business, though the filing does not disclose what share of revenue depends on that particular supplier relationship.

For the engine’s reasoning on OFIX’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.